AMI Research Updates Analyst Coverage on NeoGenomics; Maintains Outlook
(firmenpresse) - NEW YORK, NY -- (Marketwire) -- 07/28/11 -- AMI Research, () a leading provider of equity research reports and a division of IR Firm, Hawk Associates Inc., announced today that it has published updated equity research coverage on NeoGenomics, Inc. (OTCBB: NGNM) based on its .
AMI president Peter J. D'Agostino said, "NeoGenomics reported robust results. The company's performance and positive EBITDA has reinforced our outlook. We attribute the strong quarter to NGNM's newly restructured sales force, which has gained traction and we continue to expect NGNM to return to quarterly profitability during the fourth quarter with the continued momentum of its sales team and a strong pipeline of offerings in the second half of the year."
AMI Research provides an institutional-quality, equity research report detailing NeoGenomics' second quarter. The comprehensive report analyzes NGNM's key statistics, management, growth catalysts, financial outlook and valuation. The complete 8-page report is available to download for free at the AMI Research website, .
NeoGenomics Inc., () is a CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. Staffed with specially trained hematopathologists and cytogenetic professionals, NeoGenomics Laboratories offers testing in cancer genetics, flow cytometry, immunohistochemistry and molecular diagnostics through its network of regional laboratories. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, and hospitals throughout the United States. For additional information about NeoGenomics, visit .
AMI Research is a wholly owned subsidiary of Hawk Associates and provides fundamental business analysis for promising companies that do not have traditional Wall Street analyst coverage. AMI Research creates comprehensive and quality equity research reports for small cap and microcap companies that need to reach investors. These detailed reports provide retail, individual and institutional investors with an in-depth understanding of a company's intrinsic value and its technology. The AMI equity research reports detail the company's industry, strategic position, core business model, financial history and future growth catalysts. Please visit .
AMI Research abides by the Best Practice Guidelines Governing Analyst and Corporate Issuer Relationships, developed by the CFA Institute in conjunction with the National Investor Relations Institute (NIRI). The cost of a one-year continuing research program is $30,000 prepaid for four research reports. AMI does not accept payment of fees in company shares. All AMI Research and Hawk Associates personnel are prohibited from trading in securities of covered companies. Neither the analyst's compensation nor the compensation received by AMI Research is in any way related to the specific ratings or views contained in this research report.
For more information, contact Peter J. D'Agostino, president at 212.541.2465, email to: visit .
For more information, contact
Peter J. D'Agostino
President
212.541.2465
email to:
visit
405 Lexington Avenue
Chrysler Building, 26th Floor
New York, NY 10174
Tel. 212.541.2465
E-mail:
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 28.07.2011 - 12:14 Uhr
Sprache: Deutsch
News-ID 1025589
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
NEW YORK, NY
Phone:
Kategorie:
Biotech
Anmerkungen:
Diese Pressemitteilung wurde bisher 293 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AMI Research Updates Analyst Coverage on NeoGenomics; Maintains Outlook
"
steht unter der journalistisch-redaktionellen Verantwortung von
AMI Research (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
